NuCana, a UK biotech developing second-generation chemotherapies for resistant tumors, raised $100 million by offering 6.7 million shares at $15, within the range of $14 to $16. NuCana plans to list on the Nasdaq under the symbol NCNA. Citi, Jefferies and Cowen & Company acted as lead managers on the deal.
